

Keith C Bible

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8637515/keith-c-bible-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52
papers

9,096
citations

25
h-index

55
g-index

55
ext. papers

11,383
ext. citations

6.2
avg, IF

5.72
L-index

#	Paper	IF	Citations
52	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.. <i>Head and Neck</i> , 2022 ,	4.2	2
51	Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas.. <i>Journal of the Endocrine Society</i> , 2022 , 6, bvac044	0.4	0
50	Tipifarnib in Head and Neck Squamous Cell Carcinoma With Mutations. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1856-1864	2.2	31
49	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2359-2366	2.2	16
48	Anaplastic Thyroid Cancer and Primary Thyroid Lymphoma 2021 , 246-254.e3		
47	Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy. <i>Thyroid</i> , 2021 , 31, 332-333	6.2	3
46	2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2021 , 31, 337-386	6.2	66
45	Immunotherapy in Anaplastic Thyroid Cancer: Much Yet to Be Learned. <i>AACE Clinical Case Reports</i> , 2021 , 7, 334-335	0.7	1
44	Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	4
43	An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. <i>Thyroid</i> , 2020 , 30, 1254-1262	6.2	10
42	Bone metastases in thyroid cancer. <i>Journal of Bone Oncology</i> , 2020 , 21, 100282	4.5	26
41	Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma 2020 , 8,		14
40	Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. <i>Journal of the Endocrine Society</i> , 2020 , 4, bvaa069	0.4	6
39	Diagnosis and Management of Anaplastic Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019 , 48, 269-284	5.5	37
38	A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2019 , 29, 1615-1622	6.2	32
37	European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. <i>Thyroid</i> , 2019 , 29, 7-26	6.2	59
36	Anaplastic Thyroid Carcinoma 2019 , 693-700		

35	External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma. <i>Advances in Radiation Oncology</i> , 2018 , 3, 25-29	3.3	29
34	Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer. <i>Endocrine</i> , 2018 , 59, 228-229	4	3
33	Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1546-1550	3.1	25
32	Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1943-1950	5.6	54
31	Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2017 , 27, 923-927	6.2	23
30	"Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy. <i>Endocrine</i> , 2017 , 57, 187-188	4	1
29	Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 4506-4514	5.6	56
28	Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma. <i>Endocrine</i> , 2017 , 57, 220-225	4	33
27	Leveraging the immune system to treat advanced thyroid cancers. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 469-481	18.1	39
26	2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. <i>Thyroid</i> , 2016 , 26, 1-133	6.2	6910
25	Mutated BRAF and personalised medicine in differentiated thyroid cancer. <i>Lancet Oncology</i> , 2016 , 17, 1181-3	21.7	4
24	Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma. <i>International Journal of Endocrine Oncology</i> , 2016 , 3, 285-289	0.3	5
23	Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer. <i>Journal of Oncology Practice</i> , 2016 , 12, 521-2	3.1	
22	New drugs for medullary thyroid cancer: new promises?. <i>Endocrine-Related Cancer</i> , 2016 , 23, R287-97	5.7	16
21	Evolving molecularly targeted therapies for advanced-stage thyroid cancers. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 403-16	19.4	58
20	Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 4387-95	5.6	11
19	A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 1687-93	5.6	85
18	Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E936-43	5.6	9

17	Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 830-42	18.1	73
16	Protein kinase inhibitor therapy in advanced thyroid cancer: ethical challenges and potential solutions. <i>International Journal of Endocrine Oncology</i> , 2014 , 1, 145-151	0.3	7
15	Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. <i>Science Translational Medicine</i> , 2013 , 5, 166ra3	17.5	48
14	American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. <i>Thyroid</i> , 2012 , 22, 1104-39	6.2	524
13	A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. <i>Gynecologic Oncology</i> , 2012 , 127, 55-62	4.9	43
12	A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3179-84	5.6	124
11	Treating advanced radioresistant differentiated thyroid cancer. <i>Lancet Oncology, The</i> , 2012 , 13, 854-5	21.7	7
10	Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. <i>Journal of Oncology Practice</i> , 2012 , 8, e1s-5s	3.1	9
9	Systemic therapeutic approaches to advanced thyroid cancers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 389-92	7.1	2
8	Toward improved outcomes in patients with anaplastic thyroid cancer. <i>Oncology</i> , 2012 , 26, 398, 401, 406	1.8	3
7	Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. <i>American Journal of Managed Care</i> , 2012 , 18, e162-7	2.1	
6	Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1357-75	5.9	29
5	Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. <i>Thyroid</i> , 2011 , 21, 25-30	6.2	116
4	Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. <i>Lancet Oncology, The</i> , 2010 , 11, 962-72	21.7	326
3	Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 138-48	6.1	54
2	Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. <i>Clinical Cancer Research</i> , 2005 , 11, 5935-41	12.9	61
1	The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma.. <i>Blood</i> , 2004 , 104, 3461-3461	2.2	